Business Wire

Denodo Launches New Data Integration Solution in the Cloud With Denodo Standard

31.3.2021 10:00:00 EEST | Business Wire | Press release

Share

Denodo, the leader in data virtualization, today announced Denodo Standard, a new data integration solution available on leading cloud marketplaces. The new offering leverages Denodo’s modern data virtualization engine to deliver superior performance and productivity, enabling real-time analytics and data services without replicating the data into another repository. Denodo Standard lowers the barriers to begin data integration by allowing organizations to purchase it directly from their cloud marketplace of choice—AWS, Microsoft Azure, and Google Cloud Platform. Its cloud infrastructure automation and flexible by the hour pricing enables both enterprises as well as small and medium businesses to rapidly deploy it without a large commitment of time and resources.

To begin a free trial of Denodo Standard on AWS, Azure, or Google Cloud click here.

Denodo Standard provides all the capabilities to quickly get data integration projects into production. Featuring an intuitive web user interface with a powerful no-code/low-code data design studio augmented by AI-powered suggestions and the option to choose from over 150 out-of-the-box connectors to various data sources, Denodo Standard delivers data quickly. The solution enables citizen integrators to connect to cloud data warehouses, data lakes, and SaaS applications, and combine the data from these disparate sources into a unified view for consumption by business users via dashboards and reports, or developers via APIs. Denodo’s modern data virtualization connects to data sources directly where the data resides, and provides an efficient way to make the integrated data securely available without the need to collect the data into an additional repository.

Key capabilities of Denodo Standard include:

  • High performance data virtualization engine to integrate and deliver data in real time.
  • Modern, unified Web UI with SSO (single sign on).
  • Integrated Apache-Zeppelin-based data science notebook.
  • Wizard-driven visual no-code/low-code design studio with auto-suggestions and autocomplete.
  • Zero-code creation of virtual models to expose data from any source to any consumer much faster.
  • No-code creation of data APIs: GraphQL, REST, OData with OAuth, SAML and Open API support.
  • Rich Cloud Connectivity including: Amazon Redshift, Azure Synapse Analytics, Databricks Delta, Google BigQuery, cloud data stores such as AWS S3, Azure Data Lake Storage, and Google Cloud Storage and SaaS apps like Salesforce, Marketo and Google Analytics.

For organizations that need additional data management features, such as the machine learning data catalog, they can seamlessly upgrade their solution to the Denodo Platform and expand their data integration layer into an advanced logical data fabric.

Forrester VP, Principal Analyst and author of The Forrester Wave™: Enterprise Data Fabric, Q2 2020, Noel Yuhanna wrote, “Denodo’s data fabric solution integrates key data management components including data integration, data ingestion, data transformation, data governance and security to support new and emerging use cases including Customers 360, real-time and on-demand analytics, IoT analytics, and self-service analytics. In addition, Denodo’s AI and ML capabilities, and automation also continue to enhance across data fabric components.”

To understand the differences between the Denodo Standard and the Denodo Platform capabilities, click here.

“The goal of Denodo Standard is to enable organizations of all sizes to unlock the value of their data assets faster, and with a lower cost and resource commitment. By leveraging cloud infrastructure automation, usage-based pricing, and free trials in the cloud marketplaces, we have lowered barriers to start using Denodo for data integration,” said Ravi Shankar, senior vice president and chief marketing officer at Denodo. “We are excited to be able to bring the value of data virtualization to even more companies, especially small and medium-sized businesses, and we expect many of them to expand beyond their initial use quickly to the enterprise logical data fabric capabilities once they have realized the benefits and the rapid ROI Denodo provides.”

Please Tweet: News: @Denodo launches new fast and easy #dataintegration solution in the #cloud - “Denodo Standard”. Available on @awscloud @Azure @GoogleCloudTech. Free 30-day trial - https://www.denodo.com/en/denodo-platform/free-trials. Logical #datafabric #datavirtualization

About Denodo

Denodo is the leader in data virtualization providing agile, high-performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye